An anti-arrhythmic drug that is not proarrhythmic?
**Core Concept**
The question is testing the understanding of the proarrhythmic effect of anti-arrhythmic drugs, specifically the risk of inducing or worsening arrhythmias. Anti-arrhythmic drugs are classified based on their mechanism of action, and some are more likely to cause proarrhythmic effects than others.
**Why the Correct Answer is Right**
Beta blockers, such as sotalol, are not proarrhythmic because they primarily act by blocking beta-adrenergic receptors, which reduces the heart rate and contractility. This mechanism does not significantly prolong the QT interval, which is a common cause of proarrhythmia. Sotalol also has a mild effect on potassium channels, which can further reduce the risk of proarrhythmia. In contrast, class I anti-arrhythmic drugs, such as quinidine and procainamide, can prolong the QT interval and increase the risk of torsades de pointes.
**Why Each Wrong Option is Incorrect**
**Option A:** Quinidine is a class I anti-arrhythmic drug that can prolong the QT interval and increase the risk of proarrhythmia.
**Option B:** Amiodarone is a class III anti-arrhythmic drug that can prolong the QT interval and cause proarrhythmia.
**Option C:** Flecainide is a class I anti-arrhythmic drug that can prolong the QT interval and increase the risk of proarrhythmia.
**Clinical Pearl / High-Yield Fact**
Beta blockers, such as sotalol, are often used in patients with atrial fibrillation or flutter to control the ventricular rate, and are generally not proarrhythmic. However, they should be used with caution in patients with a history of torsades de pointes or QT interval prolongation.
**Correct Answer:** B. Sotalol